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ported in Table. In ERACI IV MACCE at 1 year was 2.2%, duplicating
this number up to 5.8% at 20 months, although compared to ERACI III,
ERACI IV has lower incidence of MACCE (p<0.001), the same outcome
was seen in diabetics (5.8% vs 25.5%, ERACI IV vs ERACI III respec-
tively, p<0.001) and non-diabetics (5.8% vs 12.4%, respectively p<
0.02)
Table20 months outcome ERACI III-DES ERACI IV-FRB2 p valueN patients 225 225 NADeath 7 (3.1%) 4 (1.8%) 0.54Acute myocardial
infarction (MI)10 (4.4%) 2 (0.9%) 0.01Non-fatal
cerebrovascular
accident (CVA)7 (3.1%) 0 (0.0%) 0.02Death/MI/CVA 21 (9.3%) 6 (2.7%) 0.003Unplanned
revascularization26 (11.6%) 8 (3.6%) 0.001MACCE 38 (16.9%) 13 (5.8%) <0.001Stent thrombosis
(ARC deﬁnition)7 (3.1%) 2 (0.9%) 0.17CONCLUSIONS At 20 þ/- 4 months this multicenter prospective reg-
istry showed that Firebird 2 stent used in complex lesions has a
remarkable low incidence of MACCE and other endpoints. Longer
follow-up is guaranteed to assess if these numbers remains over time.
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BACKGROUND The Svelte (New Providence, NJ) sirolimus-eluting
coronary stent utilizing a bioresorbable amino acid-based (PEA) drug
carrier is a novel stent-on-a-wire Integrated Delivery System (IDS)
consisting of a low-compliant balloon with balloon control bands
(BCBs) afﬁxed to a 0.014” integrated steerable wire with shapeable
tip. The IDS is low-proﬁle and speciﬁcally designed for use with the
transradial approach, ’slender’ PCI and direct stenting. The DIRECT I
ﬁrst-in-human study was designed to evaluate the feasibility of the
Svelte drug-eluting stent IDS.
METHODS Thirty patients with symptomatic ischemic heart disease
and a single de novo native coronary lesion suitable for percutaneous
coronary intervention were prospectively enrolled at 4 New Zealand
sites. Lesion length had to be <23 mm and the vessel reference
diameter 2.5-3.5 mm. The primary safety endpoint was 6-month target
vessel failure (TVF), deﬁned as the composite of death, target vessel
MI or clinically-driven target vessel revascularization (TLR). The pri-
mary efﬁcacy endpoint was 6-month angiographic in-stent late lumen
loss (LLL). All patients were scheduled to receive angiographic and
IVUS follow-up at baseline and 6-months, with 15 patients addition-
ally undergoing OCT analysis at the same time points. All angio-
graphic and clinical data were reviewed and adjudicated by an
independent core lab and DSMB at all reported time points.
RESULTS Twenty-nine of 30 enrolled patients completed 6-month
follow-up. Angiographic in-stent LLL was 0.22þ0.27 mm at 6-
months. Other 6-month follow-up included IVUS assessed neo-
intimal volume of 3.3þ 4.4mm3 and volume obstruction of 2.7þ4.5%.
OCT revealed 98þ4% strut coverage at a depth of 0.12þ0.06 mm.
Through 36-month followup, no patient has experienced stent
thrombosis, MACE or TVF.DIRECT First-In-Human Study 36-Mo. Follow-Up Patients (n[30)Device Success 29/30 (97%)All Death 0/30 (0%)All Myocardial Infarction 0/30 (0%)TLR, Clinically-Driven 0/30 (0%)TVR, Clinically-Driven 0/30 (0%)MACE 0/30 (0%)TVF, Angiographically-Driven 2/30 (7%)Stent Thrombosis, All Time Points 0/30 (0%)CONCLUSIONS This ﬁrst-in-human feasibility study demonstrated
minimal in-stent proliferation by angiography and conﬁrmed by IVUS,
along with near complete strut coverage by OCT. The concordant
excellent clinical outcomes, including no stent thrombosis, suggest
that the Svelte drug-eluting coronary stent IDS warrants further
evaluation. The novel approach to drug delivery may lessen the po-
tential side effects of impaired endothelial recovery, ﬁbrin deposition,
burst drug release and luminal stent strut drug residue sometimes
associated with durable polymer technologies, while direct stenting
with the IDS also minimizes procedural time and adjunctive product
use.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Coronary artery disease, Coronary stent implantation,
Direct stenting
TCT-600
Short and Mid-Term Outcomes of Diabetic Patients Treated with
Everolimus-Eluting Bioresorbable Scaffolds Versus Second-Generation
Drug Eluting Stents: a Propensity Score-Matched Analysis of ABSORB
EXTEND and SPIRIT Clinical Trials
Carlos M. Campos,1 Alexandre Abizaid,2 Adriano Caixeta,3
Antonio L. Bartorelli,4 Robert J. Whitbourn,5 Marco A. Perin6
1Hospital Israelita Albert Einstein, São Paulo, AL; 2Instituto Dante
Pazzanese de Cardiologia, São Paulo, Brazil; 3Hospital Israelita Albert
Einstein, São Paulo, Brazil; 4Centro Cardiologico Monzino-University of
Milan, Milan, Lombardia; 5Cardiovascular Research Centre, St. Vincent
Hospital Melbourne, Melbourne, Victoria; 6Hospital Albert Einstein,
Sao Paulo, Brazil
BACKGROUND There are limited data on the clinical outcomes of
diabetic patients treated with bioresorbable scaffolds (BRS). The aim
of the present analysis is to compare the occurrence of clinical
events in diabetics treated with the Absorb bioresorbable vascular
scaffold (Absorb BVS; Abbott Vascular, Santa Clara, CA) versus
everolimus-eluting metal stents (EES; XIENCE; Abbott Vascular,
Santa Clara, CA).
METHODS The present study included 812 patients in the ABSORB
EXTEND study in which a total of 215 diabetic patients were treated
with Absorb BVS. In addition, 882 diabetic patients treated with EES
in pooled data from the SPIRIT clinical program (SPIRIT II [A Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary Stent Sys-
tem], SPIRIT III [Clinical Trial of the XIENCE V Everolimus Eluting
Coronary Stent System (EECSS)], SPIRIT IV Clinical Trial [Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary Stent Sys-
tem] and XIENCE V USA) were used for comparison by applying pro-
pensity score matching using 29 different variables (217 pairs).
The primary endpoint was major adverse cardiac events (MACE),
including cardiac death, myocardial infarction, and target lesion
revascularization.
RESULTS After propensity score matching, the baseline clinical
characteristics were similar in Absorb BVS and EES groups. As shown
in Figure 1 and Table 1, diabetic patients treated with the BRS had a
similar incidence of MACE compared with diabetics treated with EES
(5.7% vs. 5.6%, respectively; HR 0.99; 0.44-2.20; P¼0.98) after 393
days of follow-up.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B245Short and Mid-Term Kaplan-Meier Estimates of MACETime After Index Procedure (days)0 37 194 393Absorb BVSPatients at Risk 215 211 206 202Number of
Events0 4 9 12% of Events 0.0% 1.9% 4.2% 5.6%XIENCEPatients at Risk 217 210 203 189Number of
Events1 4 6 12% of Events 0.5% 1.8% 2.8% 5.7%CONCLUSIONS In this largest ever patient-level pooled analysis on
treatment of diabetics patients with BRS, individuals treated with the
Absorb BVS had similar rate of major cardiac events as compared with
diabetics treated with EES.
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BACKGROUND Percutaneous coronary intervention (PCI) for unpro-
tected left main coronary artery (UPLMCA) using ﬁrst generation drug
eluting stents with ostial or mid-shaft lesions have favorable out-
comes. The safety and efﬁcacy of Xience V everolimus eluting stent
(EES) for this lesion subset is unknown.
METHODS The Xience V USA is an observational registry of 8000
patients who underwent PCI from 2008-2014, designed as a single
arm, non-randomized, post-approval study funded by Abbot Vascular.
We identiﬁed 83 patients who had PCI of a UPLMCA and compared
this to a matched cohort of 5275 patients who underwent PCI of a non-
UPLMCA lesion. The primary endpoint was the incidence of Academic
Research Consortium (ARC) deﬁned deﬁnite or probable stent
thrombosis (ST). The co-primary endpoint was a composite of cardiac
death and myocardial infarction (MI) at 1 year. The pre-speciﬁed
secondary endpoints included a composite of all cause death, MI,
repeat revascularization, target lesion failure (TLF) and major
bleeding complications. Follow-up was obtained up to 1 year and all
clinical endpoints were adjudicated by the Independent Clinical
Events Committee.
RESULTS Patients who underwent PCI of UPLMCA were older (>70
years of age, p¼0.0024), had more cardiovascular risk factors (dia-
betes mellitus 51.2% vs. 35.4%, p¼0.0036), established atherosclerotic
disease (multi-vessel coronary artery disease 53.0% vs. 24.0%,
p¼<0.0001) and renal insufﬁciency (20.7% vs. 9.9%, p¼0.0043).The UPLMCA cohort also had a lower mean EF (51.7% vs. 55.0%,
p¼0.0478). There were no differences in rates of deﬁnite or probable
stent thrombosis between UPLMCA cohort and non-UPLMCA cohort.
One year death and MI occurred in 7.6% of patients in the UPLMCA
cohort vs. 5.5% in the non-UPLMCA cohort (HR¼1.35 [0.60, 3.04],
p¼0.4611). In addition, there were no statistical signiﬁcant differences
in MACE event rates between the two groups (UPLMCA: 11.5 vs. 7.4%
non-UPLMCA, HR¼1.54 [0.79, 2.97], p¼0.1996). TLF was low at a rate
of 10.2% in the UPLMCA cohort versus 6.8% in the non- UPLMCA
cohort (HR¼1.48 [0.72, 2.98], p¼0.2721). Finally, TVR was performed
in 6.6% of patients with a UPLMCA cohort vs. 3% in the non-UPLMCA
cohort (HR¼2.21 [0.91, 5.38], p¼0.0738).
CONCLUSIONS When used in real world practice for UPLMCA PCI, the
Xience V EES is safe and effective with similar rates of stent throm-
bosis and low MACE event rates compared to non-UPLMCA PCI at one
year.
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BACKGROUND As progressively more elderly and comorbid patients
are being considered for revascularization the need for one year of
dual anti-platelets becomes of increasing concern. SYNERGY Ever-
olimus-eluting platinum chromium coronary stents allow for early
cessation of dual antiplatelet therapy (DAPT) due to complete polymer
absorption and drug elution by three months. The aim of this study
was to retrospectively assess those in our unit who have underwent
PCI with a SYNERGY stent to look for adverse outcomes post-
discontinuation of DAPT.
METHODS All patients in our unit who underwent clinically indicated
PCI with a SYNERGY stent from August 2013- December 2014 were
retrospectively analyzed. Patients who have been enrolled in multi-
center trails during the same time period are not included in this
cohort. Baseline and procedural characteristics were recorded.
Follow-up was by review of medical records or telephone contact for
post-procedural complications or adverse events.
RESULTS In total 100 patients underwent PCI with a SYNERGY
during the one-year study period. The mean age was 72.3 years
(10.0; range 41-92 years), 37% of the cohort was deﬁned as elderly
(age >75 years) and 8% deﬁned as very elderly (age >85 years). Mean
EuroSCORE was 11.37 (11.13, range 0.88-70.23). The indication for
SYNERGY stent use was as follows; frail or elderly (16%), concurrent
anticoagulation (28%) need for a non-cardiac procedure (10%),
increased bleeding risk (31%), or other (15%). NSTEMI/STEMI was the
presenting complaint in 32% of patients. The coronary disease was
complex. Left main stem was involved in (13%), multi-vessel disease
(36%), bifurcation disease requiring side-branch stenting (9%), and
37% required CTO intervention. Mean Syntax score was 22.7 (12.1,
range 6-53). The mean stent length/ patient was 75.3mm (41.5) with
1.44 0.64) lesions treated and 2.67 (1.33) stents implanted per pa-
tient. DAPT discontinuation by 3 months has occurred in 77% to date.
Despite the patient and lesion complexity, there were no thrombotic
events after discontinuation of anti-platelets (acute, sub-acute or late
stent thrombosis). Eleven patients were able to undergo non-cardiac
surgery after three months DAPT. By a minimum of six months (me-
dian follow up time per patient 341 days) follow up four patients died
from non-cardiac causes (one from cancer, one sepsis and multi-organ
failure, one ruptured abdominal aortic aneurysm and one vascular
complication post-TAVI). There were two target vessel re-
vascularizations (TVR) and one patient underwent CABG but no
incidence of stent thrombosis by the same time-point.
CONCLUSIONS The use of SYNERGY stents allows early discontin-
uation of DAPT, reducing the risk of bleeding complications and
facilitating non-cardiac procedures, without an increase in the inci-
dence of stent thrombosis. The results for TVR and clinical outcomes
are excellent for a complex patient and disease group.
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